GeneBioTech Co. Ltd
Genebiotech Co., Ltd., a specialized fermentation company, researches, develops, produces, and sells biological resources for use in animal resources, agriculture, food, medicine, etc. It offers functional feed ingredients and additives, as well as veterinary medicines. The company was founded in 1984 and is headquartered in Gongju, South Korea.
GeneBioTech Co. Ltd - Asset Resilience Ratio
GeneBioTech Co. Ltd (086060) has an Asset Resilience Ratio of 15.42% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2024)
This chart shows how GeneBioTech Co. Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down GeneBioTech Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩11.63 Billion | 15.42% |
| Total Liquid Assets | ₩11.63 Billion | 15.42% |
Asset Resilience Insights
- Good Liquidity Position: GeneBioTech Co. Ltd maintains a healthy 15.42% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
GeneBioTech Co. Ltd Industry Peers by Asset Resilience Ratio
Compare GeneBioTech Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AGP Ltd
KAR:AGP |
Pharmaceuticals | 0.71% |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 4.82% |
|
DongKoo Bio&Pharma Co. Ltd
KQ:006620 |
Pharmaceuticals | 4.28% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Sam-A Pharm. Co. Ltd
KQ:009300 |
Pharmaceuticals | 34.37% |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040 |
Pharmaceuticals | 5.22% |
|
WooGene B&G Co. Ltd
KQ:018620 |
Pharmaceuticals | 3.35% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 61.00% |
Annual Asset Resilience Ratio for GeneBioTech Co. Ltd (2009–2024)
The table below shows the annual Asset Resilience Ratio data for GeneBioTech Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 29.73% | ₩21.40 Billion | ₩71.99 Billion | -3.62pp |
| 2023-12-31 | 33.35% | ₩22.02 Billion | ₩66.02 Billion | +13.38pp |
| 2022-12-31 | 19.97% | ₩12.79 Billion | ₩64.04 Billion | -3.70pp |
| 2021-12-31 | 23.67% | ₩14.29 Billion | ₩60.37 Billion | -15.21pp |
| 2020-12-31 | 38.88% | ₩24.14 Billion | ₩62.09 Billion | +2.02pp |
| 2019-12-31 | 36.86% | ₩25.04 Billion | ₩67.93 Billion | -5.28pp |
| 2018-12-31 | 42.14% | ₩30.60 Billion | ₩72.63 Billion | +17.88pp |
| 2017-12-31 | 24.25% | ₩14.44 Billion | ₩59.54 Billion | +1.78pp |
| 2016-12-31 | 22.48% | ₩13.30 Billion | ₩59.16 Billion | +10.94pp |
| 2015-12-31 | 11.54% | ₩5.68 Billion | ₩49.21 Billion | -0.52pp |
| 2014-12-31 | 12.06% | ₩5.71 Billion | ₩47.34 Billion | +0.61pp |
| 2013-12-31 | 11.45% | ₩5.54 Billion | ₩48.35 Billion | +2.73pp |
| 2012-12-31 | 8.71% | ₩3.99 Billion | ₩45.78 Billion | -0.74pp |
| 2011-12-31 | 9.45% | ₩4.37 Billion | ₩46.27 Billion | -5.75pp |
| 2010-12-31 | 15.20% | ₩4.49 Billion | ₩29.56 Billion | -6.53pp |
| 2009-12-31 | 21.73% | ₩6.38 Billion | ₩29.36 Billion | -- |